Galderma Executed Confidentiality Agreement with Truinject
U.S. Court of Appeals for the Federal CircuitFederal · Washington, US- Document date
- Oct 1, 2026
The 30-second brief
Galderma S.A. and Truinject Corp. executed a Confidential Disclosure Agreement on October 23, 2014. The agreement governed disclosure and use of confidential information during discussions about a potential business relationship involving Truinject’s Kate technology.
Galderma S.A. holds this contract with U.S. Court of Appeals for the Federal Circuit.
Term as filed: Entered into October 23, 2014; confidentiality obligations lasted several years.
See who decides the next one before it's bid.
Get pre-RFPs freeFree account · 30-second setup · No credit card
Contract details
- Document date
- October 1, 2026
- Term
- Entered into October 23, 2014; confidentiality obligations lasted several years
- Vendor
- Galderma S.A.
- Source document
- United States Court of Appeals for the Federal Circuit Transcript Truinject Corp. v. Galderma S.A. 2026-10-01 (Transcript)
Galderma S.A.'s other public contracts
More U.S. Court of Appeals for the Federal Circuit contracts
Questions about this contract
Who was awarded the government contract by U.S. Court of Appeals for the Federal Circuit?
Galderma S.A. was awarded this government contract by U.S. Court of Appeals for the Federal Circuit, as recorded on October 1, 2026.
What type of contract is this?
This is a government contract, documented as a transcript record.
Where was this contract approved?
This contract appears in United States Court of Appeals for the Federal Circuit Transcript Truinject Corp. v. Galderma S.A. 2026-10-01 (Transcript), dated October 1, 2026 from U.S. Court of Appeals for the Federal Circuit. Civic IQ extracts contract records directly from agency meeting documents and solicitations.
What is U.S. Court of Appeals for the Federal Circuit currently buying?
Explore U.S. Court of Appeals for the Federal Circuit's vendors, signed contracts, and active RFPs on their Civic IQ agency profile.